Cargando…

Evaluation of Anlotinib Combined with Adriamycin and Ifosfamide as Conversion Therapy for Unresectable Soft Tissue Sarcomas

SIMPLE SUMMARY: Currently, as a neoadjuvant conversion therapy (NCT), pazopanib combined with neoadjuvant chemoradiotherapy could improve the pathological response of unresectable soft tissue sarcoma (uSTS). However, there is no available evidence of its effectiveness with respect to tumor reduction...

Descripción completa

Detalles Bibliográficos
Autores principales: Long, Zuoyao, Lu, Yajie, Li, Minghui, Fu, Zhanli, Akbar, Yunus, Li, Jing, Chen, Guojing, Zhang, Hong-Mei, Wang, Qi, Xiang, Liangbi, Wang, Zhen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913396/
https://www.ncbi.nlm.nih.gov/pubmed/36765658
http://dx.doi.org/10.3390/cancers15030700
_version_ 1784885417494970368
author Long, Zuoyao
Lu, Yajie
Li, Minghui
Fu, Zhanli
Akbar, Yunus
Li, Jing
Chen, Guojing
Zhang, Hong-Mei
Wang, Qi
Xiang, Liangbi
Wang, Zhen
author_facet Long, Zuoyao
Lu, Yajie
Li, Minghui
Fu, Zhanli
Akbar, Yunus
Li, Jing
Chen, Guojing
Zhang, Hong-Mei
Wang, Qi
Xiang, Liangbi
Wang, Zhen
author_sort Long, Zuoyao
collection PubMed
description SIMPLE SUMMARY: Currently, as a neoadjuvant conversion therapy (NCT), pazopanib combined with neoadjuvant chemoradiotherapy could improve the pathological response of unresectable soft tissue sarcoma (uSTS). However, there is no available evidence of its effectiveness with respect to tumor reduction and surgical margins. In China, anlotinib is a novel tyrosine kinase inhibitor (TKI) that is approved for STS. In this study, adding anlotinib to adriamycin and ifosfamide resulted in an increased rate of tumor regression, surgical conversion and R0 resection in patients with uSTS, particularly for synovial sarcoma and liposarcoma. Severe toxicities are more frequent than monotherapy, but they are controllable. ABSTRACT: (1) Background: This study investigated the safety and efficiency of adriamycin and ifosfamide combined with anlotinib (AI/AN) as a neoadjuvant conversion therapy in uSTS. (2) Methods: Patients with uSTS were eligible to receive AI/An, including adriamycin (20 mg/m(2)/d) and ifosfamide (3 g/m(2)/d) for the first to the third day combined with anlotinib (12 mg/d) for 2 weeks on/1 week off, all of which combine to comprise one cycle. Surgery was recommended after four cycles of treatment. (3) Results: A total of 28 patients were enrolled from June 2018 to December 2020. The best tumor responses included eight patients with partial responses and 20 with a stable disease. Patients with synovial sarcoma and liposarcoma had a significant decrease in the number of tumors compared with fibrosarcoma (p = 0.012; p = 0.042). The overall response rate and disease control rate were 28.57% and 100%, respectively. In total, 24 patients received surgery, while the rates of limb salvage and R0 resection were 91.67% (n = 22/24) and 87.50% (n = 21/24), respectively. Until the last follow-up visit, the mean PFS and RFS were 21.70 and 23.97 months, respectively. During drug administration, 67.87% of patients had grade ≥3 AEs. No treatment-related death occurred. (4) Conclusions: AI/AN followed by surgery showed favorable efficiency and manageable safety in patients with uSTS. A randomized controlled study with a large cohort should be performed for further investigations.
format Online
Article
Text
id pubmed-9913396
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99133962023-02-11 Evaluation of Anlotinib Combined with Adriamycin and Ifosfamide as Conversion Therapy for Unresectable Soft Tissue Sarcomas Long, Zuoyao Lu, Yajie Li, Minghui Fu, Zhanli Akbar, Yunus Li, Jing Chen, Guojing Zhang, Hong-Mei Wang, Qi Xiang, Liangbi Wang, Zhen Cancers (Basel) Article SIMPLE SUMMARY: Currently, as a neoadjuvant conversion therapy (NCT), pazopanib combined with neoadjuvant chemoradiotherapy could improve the pathological response of unresectable soft tissue sarcoma (uSTS). However, there is no available evidence of its effectiveness with respect to tumor reduction and surgical margins. In China, anlotinib is a novel tyrosine kinase inhibitor (TKI) that is approved for STS. In this study, adding anlotinib to adriamycin and ifosfamide resulted in an increased rate of tumor regression, surgical conversion and R0 resection in patients with uSTS, particularly for synovial sarcoma and liposarcoma. Severe toxicities are more frequent than monotherapy, but they are controllable. ABSTRACT: (1) Background: This study investigated the safety and efficiency of adriamycin and ifosfamide combined with anlotinib (AI/AN) as a neoadjuvant conversion therapy in uSTS. (2) Methods: Patients with uSTS were eligible to receive AI/An, including adriamycin (20 mg/m(2)/d) and ifosfamide (3 g/m(2)/d) for the first to the third day combined with anlotinib (12 mg/d) for 2 weeks on/1 week off, all of which combine to comprise one cycle. Surgery was recommended after four cycles of treatment. (3) Results: A total of 28 patients were enrolled from June 2018 to December 2020. The best tumor responses included eight patients with partial responses and 20 with a stable disease. Patients with synovial sarcoma and liposarcoma had a significant decrease in the number of tumors compared with fibrosarcoma (p = 0.012; p = 0.042). The overall response rate and disease control rate were 28.57% and 100%, respectively. In total, 24 patients received surgery, while the rates of limb salvage and R0 resection were 91.67% (n = 22/24) and 87.50% (n = 21/24), respectively. Until the last follow-up visit, the mean PFS and RFS were 21.70 and 23.97 months, respectively. During drug administration, 67.87% of patients had grade ≥3 AEs. No treatment-related death occurred. (4) Conclusions: AI/AN followed by surgery showed favorable efficiency and manageable safety in patients with uSTS. A randomized controlled study with a large cohort should be performed for further investigations. MDPI 2023-01-23 /pmc/articles/PMC9913396/ /pubmed/36765658 http://dx.doi.org/10.3390/cancers15030700 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Long, Zuoyao
Lu, Yajie
Li, Minghui
Fu, Zhanli
Akbar, Yunus
Li, Jing
Chen, Guojing
Zhang, Hong-Mei
Wang, Qi
Xiang, Liangbi
Wang, Zhen
Evaluation of Anlotinib Combined with Adriamycin and Ifosfamide as Conversion Therapy for Unresectable Soft Tissue Sarcomas
title Evaluation of Anlotinib Combined with Adriamycin and Ifosfamide as Conversion Therapy for Unresectable Soft Tissue Sarcomas
title_full Evaluation of Anlotinib Combined with Adriamycin and Ifosfamide as Conversion Therapy for Unresectable Soft Tissue Sarcomas
title_fullStr Evaluation of Anlotinib Combined with Adriamycin and Ifosfamide as Conversion Therapy for Unresectable Soft Tissue Sarcomas
title_full_unstemmed Evaluation of Anlotinib Combined with Adriamycin and Ifosfamide as Conversion Therapy for Unresectable Soft Tissue Sarcomas
title_short Evaluation of Anlotinib Combined with Adriamycin and Ifosfamide as Conversion Therapy for Unresectable Soft Tissue Sarcomas
title_sort evaluation of anlotinib combined with adriamycin and ifosfamide as conversion therapy for unresectable soft tissue sarcomas
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913396/
https://www.ncbi.nlm.nih.gov/pubmed/36765658
http://dx.doi.org/10.3390/cancers15030700
work_keys_str_mv AT longzuoyao evaluationofanlotinibcombinedwithadriamycinandifosfamideasconversiontherapyforunresectablesofttissuesarcomas
AT luyajie evaluationofanlotinibcombinedwithadriamycinandifosfamideasconversiontherapyforunresectablesofttissuesarcomas
AT liminghui evaluationofanlotinibcombinedwithadriamycinandifosfamideasconversiontherapyforunresectablesofttissuesarcomas
AT fuzhanli evaluationofanlotinibcombinedwithadriamycinandifosfamideasconversiontherapyforunresectablesofttissuesarcomas
AT akbaryunus evaluationofanlotinibcombinedwithadriamycinandifosfamideasconversiontherapyforunresectablesofttissuesarcomas
AT lijing evaluationofanlotinibcombinedwithadriamycinandifosfamideasconversiontherapyforunresectablesofttissuesarcomas
AT chenguojing evaluationofanlotinibcombinedwithadriamycinandifosfamideasconversiontherapyforunresectablesofttissuesarcomas
AT zhanghongmei evaluationofanlotinibcombinedwithadriamycinandifosfamideasconversiontherapyforunresectablesofttissuesarcomas
AT wangqi evaluationofanlotinibcombinedwithadriamycinandifosfamideasconversiontherapyforunresectablesofttissuesarcomas
AT xiangliangbi evaluationofanlotinibcombinedwithadriamycinandifosfamideasconversiontherapyforunresectablesofttissuesarcomas
AT wangzhen evaluationofanlotinibcombinedwithadriamycinandifosfamideasconversiontherapyforunresectablesofttissuesarcomas